ClinicalTrials.gg
CompletedNCT00245713Updated Nov 26, 2013

Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.

A Phase 4 interventional study of levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Completed. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-11-26.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
17th of 18
40 · median 173
Started
2003
with 1 other
Phase 4
7 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
10 of 18
UCB Pharma

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 17th largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 4, and was the 9th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

Effect of adjunctive levetiracetam on polysomnography in adults with partial-onset epilepsy receiving a classical antiepileptic drug

03

Conditions studied

  • Epilepsy, Partial

Browse trials for

Keywords

  • Levetiracetam, adult, partial-onset epilepsy, antiepileptic
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have partial onset epilepsy and have been taking carbamazepine or phenytoin at a stable dose for a period of 4 weeks prior to the selection visit
  • Subjects must have controlled partial onset seizures which can potentially benefit from adjunctive treatment

Exclusion criteria

Exclusion Criteria:

  • Subjects dosing with LEV two weeks prior to the selection visit
  • Subjects using more than one AED
  • Subjects with specific and non-specific sleep disorders
05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
40 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Changes from Baseline to visit 7 in percent REM, percent slow wave sleep (stages 3 and 4), and sleep efficiency (which is total sleep time ÷ time in bed defined as lights out), with particular focus on sleep efficiency.

Secondary outcomes

  1. Secondary endpoints are based on the changes from Baseline to visit 7

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Nov 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2005
First posted
Oct 28, 2005
Start
Mar 2003
Primary completionActual
Nov 2004
CompletionActual
Nov 2004
Last update
Nov 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00245713
Lead sponsor
UCB Pharma
First posted
Oct 28, 2005
Start date
Mar 2003
Primary completion
Nov 2004
Completion
Nov 2004
Last update
Nov 26, 2013

Study contacts

UCB Clinical Trial Call Center
study director · UCB Pharma
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion